AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Poxel Announces Participation at ODDO BHF Forum

December 19, 2019 GMT

LYON, France--(BUSINESS WIRE)--Dec 19, 2019--

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will participate at the ODDO BHF Forum, which is being held on January 9-10, 2020, in Lyon, France. Members from the Poxel management team will be available to participate in one-on-one meetings with investors.

About Poxel SA
Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 T rials of IM eglimin for E fficacy and S afety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a Mitochondrial Pyruvate Carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191219005428/en/

CONTACT: Poxel SA

Jonae R. Barnes

Senior Vice President, Investor Relations and Public Relations

jonae.barnes@poxelpharma.com

+1 617 818 2985Aurélie Bozza

Investor Relations & Communication Director

aurelie.bozza@poxelpharma.com

+33 6 99 81 08 36Investor relations / Media - EU/US

Trophic Communications

Stephanie May or Joanne Tudorica

may@trophic.euortudorica@trophic.eu

+49 89 238 877 34 or +49 171 185 56 82Investor relations / Media - France

NewCap

Alexia Faure / Arthur Rouillé

poxel@newcap.eu

+33 1 44 71 94 94

KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY DIABETES HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: Poxel SA

Copyright Business Wire 2019.

PUB: 12/19/2019 11:45 AM/DISC: 12/19/2019 11:45 AM

http://www.businesswire.com/news/home/20191219005428/en